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A B S T R A C T
In the isolated rat carotid artery, the endocannabinoid anandamide induces endothelium-dependent relaxation
via activation of the enzyme sphingosine kinase (SK). This generates sphingosine-1-phosphate (S1P) which can
be released from the cell and activates S1P receptors on the endothelium. In anaesthetised mice, anandamide has
a well-characterised triphasic effect on blood pressure but the contribution of SK and S1P receptors in mediating
changes in blood pressure has never been studied. Therefore, we assessed this in the current study.
The peak hypotensive response to 1 and 10mg/kg anandamide was measured in control C57BL/6 mice and in
mice pretreated with selective inhibitors of SK1 (BML-258, also known as SK1-I) or SK2 ((R)-FTY720 methy-
lether (ROMe), a dual SK1/2 inhibitor (SKi) or an S1P1 receptor antagonist (W146). Vasodilator responses to S1P
were also studied in isolated mouse aortic rings.
The hypotensive response to anandamide was significantly attenuated by BML-258 but not by ROMe.
Antagonising S1P1 receptors with W146 completely blocked the fall in systolic but not diastolic blood pressure in
response to anandamide. S1P induced vasodilation in denuded aortic rings was blocked by W146 but caused no
vasodilation in endothelium-intact rings.
This study provides evidence that the SK1/S1P regulatory-axis is necessary for the rapid hypotension induced
by anandamide. Generation of S1P in response to anandamide likely activates S1P1 to reduce total peripheral
resistance and lower mean arterial pressure. These findings have important implications in our understanding of
the hypotensive and cardiovascular actions of cannabinoids.
1. Introduction
In a previous study (Mair et al., 2010), we identified a novel
pathway which may underlie the endothelium-dependent vasodilator
effects of anandamide in the rat coronary artery. This pathway involves
the activation of sphingosine kinase 1 (SK1), the enzyme that catalyses
the phosphorylation of sphingosine to produce sphingosine-1-phos-
phate (S1P), release of S1P and activation of S1P receptors on the
vascular endothelium. Thus we proposed that this pathway allows S1P
to access local populations of S1P receptors (Mair et al., 2010). Since
anandamide has well-documented effects on blood pressure (BP), we
sought to investigate if SK is required for anandamide to induce hy-
potension in anaesthetised mice and if S1P receptors are involved.
Anandamide (AEA) is an endogenously-generated cannabinoid
which activates the endocannabinoid receptors CB1 and CB2 and the
vanilloid transient receptor potential channels of V1 type (TRPV1) re-
ceptor (Stanley and O'Sullivan, 2014). These endocannabinoids might
also activate as yet uncharacterised receptors within the cardiovascular
system, such as the orphan G protein-coupled receptors (GPCRs),
GPR55 (Ryberg et al., 2007; Johns et al., 2007) and GPR119 (Overton
et al., 2006). Both GPR55 and GPR119 have been demonstrated to bind
endocannabinoids and evidence also exists for a non-CB1/non-CB2 en-
dothelial receptor, CBx (Offertaler et al., 2003; Zakrzeska et al., 2010)
although this is controversial and requires further investigation. Both
CB1 and CB2 receptors are located within the cardiovascular system
(Batkai et al., 2004) and CB2 receptors are also present on circulating
immune cells (Munro et al., 1993). The cardiovascular actions of en-
docannabinoids are complex and vary not only between species but also
with experimental conditions (Randall et al., 2004). In anaesthetised
animals, intravenous (i.v.) administration of AEA evokes a triphasic
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response (Lake et al., 1997; Malinowska et al., 2001; Pacher et al.,
2004). The initial phase I is characterised by a rapid and transient drop
in BP which is accompanied by bradycardia, increased total peripheral
resistance (TPR) and reduced cardiac contractility. Phase II consists of a
short pressor response, marked by an increase in BP, cardiac con-
tractility and mesenteric blood flow. This is followed by a more pro-
longed (~10min) hypotension, a reduction in mesenteric blood flow,
cardiac contractility and heart rate (HR) (Malinowska et al., 2012). The
hypotensive phase I response is thought to involve a vagal-mediated
Bezold-Jarisch reflex and the activation of TRPV1 (Malinowska et al.,
2001; Pacher et al., 2004). TRPV1 is expressed widely in the cardio-
vascular system, including on blood vessels (Zhang et al., 2015;
Fernandes et al., 2012) and so AEA, or mechanisms downstream could
affect blood vessels as well as the heart during phase I. However, to date
no study has addressed whether the sphingolipid pathway is involved in
mediating the phase I hypotensive response to AEA. Based on our in
vitro data in the rat coronary artery (Mair et al., 2010), we hypothesised
that generation of S1P in response to i.v. administration of AEA may
underlie the phase I hypotensive response in the mouse.
S1P is a lysophospholipid derived from phosphorylation of sphin-
gosine. S1P can function inside cells to bind to target proteins such as
histone deacetylase 1/2 (reviewed in Pyne and Pyne, 2011). Extra-
cellular S1P can also bind to high affinity GPCRs (S1P1–5), of which
S1P1, S1P2 and S1P3 are localised within the cardiovascular system
(Pyne and Pyne, 2011). S1P mainly functions as a pro-survival signal-
ling molecule while sphingosine is associated with pro-apoptotic
pathways and is an important regulator of cell stress responses (Hannun
and Obeid, 2002). SK catalyses the formation of S1P from sphingosine
and hence represents a key checkpoint in the regulation of the relative
levels of sphingosine and its precursor, ceramide, and S1P; termed the
sphingolipid rheostat. Two distinct SK isoforms have been identified
called SK1 and SK2 (Kohama et al., 1998; Liu et al., 2000). The two
isoforms differ substantially in their tissue expression, substrate and
inhibitor specificity, kinetic properties as well as their cellular locali-
sation (Chan and Pitson, 2013). SK1 is predominately localised in the
cytoplasm of cells (Kohama et al., 1998; Olivera et al., 1998). In re-
sponse to agonist-stimulation, SK1 is phosphorylated, activated several-
fold and translocated to the plasma membrane (Pitson et al., 2003). In
contrast, phosphorylation of a nuclear export sequence in SK2 promotes
its export from the nucleus (Ding et al., 2007).
SK/S1P has been implicated in negatively regulating BP in hy-
pertension (Spijkers et al., 2012) and growing evidence suggests a link
between the sphingolipid and endocannabinoid signalling systems.
Phylogenetic analysis has identified a ~20% sequence homology be-
tween S1P and CB receptors and CB1 activation was shown to activate
enzymes involved in sphingolipid metabolism (Galve-Roperh et al.,
2000; Gustafsson et al., 2009). Furthermore, we (Mair et al., 2010) and
others have presented evidence to suggest that S1P can act as an agonist
at CB receptors and that the vascular effects of AEA require SK1 (Paugh
et al., 2006). Therefore, the aim of this study was to identify the con-
tribution of the two SK isoforms to the phase I hypotensive action of
AEA in vivo. We also examined whether S1P released from cells as a
consequence of the activation of SK uses S1P receptors to induce this
hypotensive response.
2. Materials and methods
2.1. In vivo experiments
All animal care and experimental procedures were in accordance
with the UK Animals (Scientific Procedures) Act 1986 and data are
reported according to the ARRIVE (Animal Research: Reporting of In
Vivo Experiments) guidelines. Ethical approval was granted by the
University Ethics Committee and conformed to institutional regulations
at the University of Glasgow. All mice used in the study were bred in the
University of Glasgow, kept on a 12 h light/dark cycle and fed ad
libitum.
2.2. Administration of drugs
Twenty four hours prior to BP measurements, animals were ran-
domly assigned to receive one of the following treatments via in-
traperitoneal (i.p.) injection: 75mg/kg of the dual SK1/2 inhibitor, 2-
(p-hydroxyanilino)-4-(p-chlorophenyl) thiazole (SKi, Calbiochem, San
Diego, CA, U.S.A. (French et al., 2003)); 75mg/kg of the selective SK1
inhibitor, (2 R,3 S,4E)-N-methyl-5-(4′-pentylphenyl)-2-aminopent-4-
ene-1,3-diol (BML-258 (also known as SK1-I), Tocris Bioscience, Bristol,
U.K. (Paugh et al., 2008)); 75mg/kg of the selective SK2 inhibitor, (R)-
FTY720 methyl ether (ROMe) (Lim et al., 2011) or the equivalent vo-
lume of vehicle (0.1 ml of dimethyl sulphoxide (DMSO)). To test the
effect of blocking S1P1 on the hypotensive response to anandamide, we
employed 10mg/kg of the selective antagonist, (R)-3-amino-4-(3-hex-
ylphenylamino)-4-oxobutylphosphonic acid trifluoroacetate (W146,
Avanti Polar Lipids, Alabaster, U.S.A. (Tarrason et al., 2011)), which
was injected 30min prior to BP measurement. Control animals received
an equivalent volume of solvent (0.1 ml DMSO). All doses of drugs used
were based on previously published studies.
2.3. BP recording
Haemodynamic measurements were performed under inhalational
anaesthesia. Male C57BL/6 mice (mean weight 24 ± 3.5 g) were in-
duced using 3% isoflurane supplemented with oxygen and maintained
on 1.5% isoflurane in oxygen throughout the procedure. The left carotid
artery was exposed and cannulated with a heparinised saline-con-
taining cannula (Harvard Apparatus, Kent, U.K.) connected to a Bio-Pac
Student Lab Pro pressure transducer and recorder (BioPac Systems,
Norfolk, U.K.). The right jugular vein was cannulated for administration
of AEA (1 or 10mg/kg in tocrisolve), methanandamide (1 or 10mg/kg
in tocrisolve) or the equivalent volume of tocrisolve (0.1 ml per injec-
tion). In all animals, BP was recorded continuously and 5min was al-
lowed between injections of AEA, methanandamide or vehicle at which
time BP had stabilised. All injections were given rapidly over 1–2 s.
2.4. Wire myography
After mice (mean weight 33 ± 1.8 g) were killed with a rising
concentration of CO2, the aorta was removed and transferred to oxy-
genated modified Krebs-Henseleit (KH) solution containing (in mM):
118 NaCl, 25 NaHCO3, 4.7 KCl, 1.2 KH2PO4, 1 MgSO4, 2.5 CaCl2,
11 glucose. The aorta was used in these experiments as, although it is
not a resistance vessel, the functional responses and S1P receptor po-
pulations have recently been reported (Roviezzo et al., 2014). The aorta
was carefully dissected to remove surrounding connective tissue and, in
some experiments, the lumen was rubbed gently to remove en-
dothelium and mounted in a wire myograph containing KH solution at
37 °C and aerated with 95% O2/5% CO2. After a period of equilibration,
the vessels were placed under an optimum resting tension of 1 g for at
least 30min then challenged with sequential addition of 40 and 80mM
KCl to assess viability. In experiments with denuded vessels, successful
removal of the endothelium was verified by contracting with 30 nM of
the thromboxane A2 analogue, U46619 and adding 10 µM acetylcho-
line. Lack of relaxation in response to acetylcholine indicated no en-
dothelium was present.
To assess the effects of increasing concentrations of sphingosine,
S1P and AEA on aortic vascular tone, vessels were pre-contracted with
30 nM U46619. A dose-response curve was generated by the cumulative
addition of AEA (1 nM to 100 µM), sphingosine and S1P (1 nM to 5 µM)
in half-log molar concentrations. In some experiments, the effect of the
dual SK1/2 inhibitor SKi, on agonist-induced relaxation was in-
vestigated. In these experiments, 10 µM SKi was added 5min prior to
the addition of U46619 and was present throughout the generation of
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the dose-response curve. To investigate the receptor subtypes re-
sponsible for the S1P-mediated vasodilatation in the mouse aorta, rings
were pre-incubated for 10min with either 10 µM W146 or 10 µM of the
combined S1P1/3 antagonist, 2-amino-N-(3-octylphenyl)-3-(phospho-
nooxy)-propanamide (VPC 23019, Tocris Bioscience, Bristol, U.K.
(Davis et al., 2005)). Inhibitors remained in the bath for the duration of
the experiment. For all experiments, sphingosine and S1P were pre-
pared and diluted in a 4mg/ml aqueous solution of bovine serum al-
bumin (BSA) and stored on ice (Rosen et al., 2009).
2.5. Immunohistochemistry
For analysis of S1P1 expression and location, aortae from vehicle-
and W146-treated mice were carefully excised following cervical dis-
location. The aortae were cleared of any surrounding fat and connective
tissue and fixed in 10% formalin at 4 °C for 24 h. Following fixation, the
aortae were dehydrated, paraffin-embedded and sectioned on a rotary
microtome at 5 µm. Slides were subjected to a standard im-
munohistochemical protocol to study S1P1 expression (Cuevas et al.,
1994). Briefly, antigens were retrieved by microwave pressure cooking
in citric acid followed by blocking of endogenous peroxidase and non-
specific binding. Primary antibody against S1P1 was then incubated
overnight at 4 °C (1:150 dilution in 1% (w/v) BSA in PBS, Abcam,
Cambridge, U.K.). A peroxidase-labelled DAB method followed by
counterstaining using haematoxylin was used to visualise the location
of S1P1 on the aortae.
2.6. Statistical analysis
Data are expressed as mean ± S.E.M. where n is the number of
different animals or number of aortae from individual animals. All
statistical analyses were performed using GraphPad Prism 5.0 (La Jolla,
CA, U.S.A.). Differences in baseline mean arterial blood pressure (MAP)
were analysed by either unpaired t-test or one-way ANOVA with
Dunnett's post hoc test. The percentage change in MAP and HR in re-
sponse to anandamide ± SK inhibitors or S1P receptor antagonists
were analysed by two-way ANOVA with Bonferroni's post-hoc analysis.
For myography experiments, comparisons of drug incubation on
U46619 contraction were analysed by either unpaired Student's t-test or
one-way ANOVA while dose-response curves were analysed using two-
way ANOVA. P < 0.05 was considered statistically significant.
3. Results
3.1. Effects of SK inhibitors
AEA induced a dose-dependent, transient fall in BP, followed by a
short pressor response and a longer lasting hypotension (Fig. 1). In all
experimental groups, MAP had recovered to a level not significantly
different from pre-injection levels 5min after the 1mg/kg dose of AEA
(Supplementary Fig. 1). Thus, the initial dose of AEA is unlikely to have
influenced the response to the second injection of 10mg/kg AEA.
Baseline mean arterial blood pressure (MAP) was 92.6 ± 3.0mmHg in
vehicle-treated mice (n= 12) which was not significantly different
from animals injected with the dual SK1/2 inhibitor, SKi (75mg/kg)
24 h previously (91.6 ± 2.6mmHg; n= 12, Fig., 2A). However,
baseline HR was reduced by SKi treatment (495.4 ± 22.4 bpm in
control; n= 12 versus 421.3 ± 22.3 bpm in SKi group; n=12). Since
baseline blood pressure data were very consistent within experimental
groups, reductions are reported as % values. In mice treated with SKi,
the hypotensive response to AEA was inhibited (20.7 ± 3.7% of
baseline with vehicle (n= 8) versus 6.7 ± 1.9% of baseline with SKi
(n=7), Fig. 2B). AEA also had a tendency to lower HR during phase I
in control and SKi-treated animals although this was not significant
(455.0 ± 40.8 bpm in DMSO-treated animals versus 412.0 ± 28.5
bpm in SKi-treated animals following AEA administration; n=5–8).
Methanandamide (10mg/kg) also caused a rapid phase I hypotensive
response but this was smaller compared to AEA (9.9 ± 6.6% of base-
line value; n= 3). Tocrisolve, the AEA vehicle, had no effect on MAP
(Fig. 2B) or on HR (data not shown).
In order to determine which SK isoform was important in mediating
the AEA-induced hypotension, these experiments were repeated using
SK1- and SK2-selective inhibitors, BML-258 (SK1-I) and ROMe, re-
spectively. Neither inhibitor had any effect on baseline HR but ROMe
and, to a greater extent, BML-258 significantly lowered baseline MAP
(Fig. 2C). In mice treated with the vehicle, the maximum phase I hy-
potensive response to AEA was 16.5 ± 8.2% of baseline MAP at 1mg/
kg (n= 9) and 43.6 ± 7.2% of baseline MAP at 10mg/kg (n=9;
Fig. 2D). In mice pretreated with BML-258, the hypotension induced by
AEA was abolished and instead a small increase in MAP was observed
(6.8 ± 3.6% at 1mg/kg (n= 5) and 4.8 ± 7.8% at 10mg/kg
(n= 5)). Conversely, ROMe had no significant effect on the hypoten-
sion induced by AEA (Fig. 2D). As found previously, AEA caused some
transient bradycardia but there were no significant differences in the
magnitude of the bradycardia across the groups at either dose of AEA
(Supplementary Fig. 2). Tocrisolve treatment had no effect on either
MAP or HR in either vehicle-, BML-258- or ROMe-pretreated animals.
3.2. Effect of an S1P1 antagonist
Our data suggest that injection of AEA causes the generation of S1P
catalysed by SK1 which is responsible for the phase I hypotensive effect.
We therefore hypothesised that the vascular component of the hypo-
tensive response may be mediated via activation of S1P1 on the vas-
culature. To test this, we pretreated mice with the selective S1P1 an-
tagonist W146 (10mg/kg) for 30min before recording the responses to
AEA. W146 treatment did not significantly affect baseline MAP
(Fig. 3A) but attenuated the hypotensive response to 10mg/kg AEA
(Fig. 3B). Tocrisolve had no effect on MAP or HR in either the vehicle-
or W146-treated mice (data not shown). Interestingly, when systolic
and diastolic pressure changes were analysed, it could be seen that
W146 completely attenuated the fall in systolic pressure induced by
10mg/kg AEA (-15.7 ± 2.5mmHg in vehicle-treated mice (n=8)
versus 0.04 ± 2.3mmHg in W146-treated mice (n= 8); Fig. 3C) but
had no effect on the diastolic pressure (data not shown). Thus, mice
treated with W146 experience a significant increase in pulse pressure
following 10mg/kg AEA injection (36.6 ± 6.3mmHg with vehicle
(n= 5) versus 55.0 ± 2.2mmHg with W146 (n=5)). Again, AEA-in-
duced a bradycardic effect which was not significantly different in
W146 versus vehicle-treated mice (data not shown).
Fig. 1. Representative experimental recording showing the changes in BP in-
duced by i.v. injection of two doses of anandamide (1 and 10mg/kg) in mice.
Arrows indicate the injections of anandamide which were administered at 5min
intervals.
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3.3. Vasodilation to S1P in isolated mouse aortae
In denuded, pre-contracted mouse aortic rings, addition of sphin-
gosine or S1P (1 nM to 5 µM) prepared in 4mg/ml BSA solution (Rosen
et al., 2009) induced a dose-dependent relaxation (Fig. 4). SKi had no
significant effect on the pre-contraction to U46619 (Fig. 4A). In vessels
incubated with SKi prior to pre-contraction with U46619, the relaxation
to sphingosine was markedly attenuated (maximum relaxation of
11.4 ± 4.4% with SKi, n= 3 versus 25.2 ± 8.0% with vehicle, n= 9,
Fig. 4B). In endothelium intact, pre-contracted rings, addition of S1P
did not induce any relaxation (n= 5; data not shown) and sphingosine
only induced a very small relaxation (maximum of 6.8 ± 2.8%; n= 6)
which was not sensitive to SKi (maximum relaxation 7.6 ± 2.9%;
n=5). Similarly, AEA only induced a small relaxation at a con-
centration of 100 µM (5.9 ± 4.8% (n=5)) and produced no relaxation
in denuded rings (n=5; data not shown).
In order to determine which S1P receptors on the vasculature are
important in the S1P-mediated vasodilation in denuded mouse aortae,
vessels were pretreated with either W146 (a S1P1 antagonist) or VPC
23019 (a S1P1/3 antagonist). Neither W146 nor VPC 23019 affected the
preconstriction of the aorta in response to U46619 (Fig. 4C). S1P in-
duced a maximum relaxation of 32.7 ± 5.6% (Fig. 4D) which was al-
most completely abolished by W146 (maximum relaxation reduced to
6.5 ± 3.1%; n=8) or VPC 23019 (maximum relaxation was reduced
to -1.0 ± 7.6%; n=5). This suggests that S1P1 is the receptor subtype
responsible for the vasodilator effect of S1P at the level of vascular
smooth muscle cells (VSMCs). To exclude the possibility that VPC23019
and W146 were inhibiting relaxation to S1P by acting as direct BKCa
inhibitors, relaxation to the BKCa activator NS1619 was studied. In
endothelium-intact rings, NS1619 induced a relaxation at 30 µM which
was unaffected by pretreatment with either 10 µM VPC 23019 or 10 µM
W146 (Fig. 4E).
3.4. Distribution of S1P1 on the mouse aorta
In human tissue, although S1P1 is abundantly expressed on cardi-
omyocytes and endothelial cells of coronary vessels, it was not found on
the aortic smooth muscle, where S1P2 and S1P3 were expressed
Fig. 2. Effect of pretreatment with SK inhibitors on the peak hypotensive response to i.v. anandamide administration. (A) Mice were pre-treated with either vehicle or
dual SK1/2 inhibitor, SKi (75mg/kg) for 24 h prior to baseline MAP measurement. n=12. (B) Baseline values were compared to the peak hypotensive response
following tocrisolve or anandamide injection. **P < 0.01, n= 4–8, two-way ANOVA. (C) Mice were pre-treated with either vehicle or the selective SK1 or SK2
inhibitors (75mg/kg), BML-258 or ROMe respectively, for 24 h prior to baseline MAP measurement. *P < 0.05 and ***P < 0.001, n= 5–12, one-way ANOVA. (D)
Baseline values were compared to the peak hypotensive response following increasing doses of anandamide. *P < 0.05, n= 5–9, two-way ANOVA.
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(Mazurais et al., 2002). Since our data suggest that S1P1 is responsible
for S1P-mediated dilation in denuded mouse aortae, we examined S1P1
expression on the smooth muscle and endothelium by im-
munohistochemistry. Expression of S1P1 was found throughout the
media of the vessels with strong immunostaining in the endothelium.
Pretreatment of the mice with W146 did not affect receptor expression
pattern or density (Fig. 5).
4. Discussion
In this study, we have described a novel mechanism which underlies
the phase I hypotensive response to the endocannabinoid AEA in the
anaesthetised mouse. The response appears to be dependent on SK1
activity but not SK2 activity, and at least part of the hypotensive re-
sponse is via activation of S1P1, presumably through generation and
release of S1P. The in vitro data indicate that while S1P has a vasodi-
lator effect via activation of S1P1, this is at the level of the medial
smooth muscle rather than the endothelium. Thus, the AEA-induced
activation of SK and generation of S1P may occur within resistance
vessels but does not occur within conduit vessels such as the aorta.
4.1. Effect of SK inhibition on basal MAP
Both BML-258 and ROMe induced a lowering of basal MAP when
injected 24 h before measurement. This was particularly marked with
the selective SK1 inhibitor BML-258, where the reduction was around
40%. This is in contrast to SK1 knockout mice which present with no
change in MAP (Olivera et al., 2010), although this may be due to some
compensatory mechanism. Similarly, SKi had no effect on MAP despite
lowering basal HR and this may represent an off-target effect of SKi,
The lowering of basal MAP strongly suggests that the SK1/S1P-axis
participates in the physiological regulation of BP. However, since W146
did not induce any change in basal MAP, it seems that either S1P1 is not
involved in maintenance of basal MAP or other S1P receptor subtypes
can be activated to maintain BP when S1P1 is blocked. Other studies
(Spijkers et al., 2012) have similarly observed a BP reduction in nor-
motensive rats treated with FTY720 or N-N-dimethylsphingosine, both
of which are SK1 inhibitors (Tonelli et al., 2010). The reduction in basal
MAP could be due to effects on TPR or cardiac output (CO) or a com-
bination of both. Basal HR was unchanged by SK inhibition but negative
inotropic effects could account for a lowering of CO. However, most
studies have claimed that S1P has negative inotropic and chronotropic
effects (Landeen et al., 2008; Means et al., 2008); therefore, blocking
generation of S1P in vivo would be expected to raise CO rather than
lowering it. A reduction in TPR in response to blockade of SK is more
likely. Indeed, several studies have indicated that an action of S1P on
S1P2 can cause vasoconstriction of resistance vessels (Bischoff et al.,
2000b, 2000a) and mice lacking S1P2 exhibit an overall reduction in
vascular tone and contractile responsiveness (Lorenz et al., 2007). Ex-
pression of dominant negative SK1 in VSMCs and resistance arteries
decreases vascular tone and myogenic responsiveness (Bolz et al.,
2003), all of which could result in a lowering of basal MAP.
4.2. SK in anandamide-induced hypotension
Both 1 and 10mg/kg AEA dose-dependently induced a rapid fall in
MAP and HR which was of a similar magnitude to that reported pre-
viously (Lake et al., 1997; Malinowska et al., 2001). In a small number
of experiments the stable anandamide analogue methanandamide also
produced a rapid fall in MAP although this was of a smaller magnitude,
suggesting that arachidonic acid metabolites of AEA may play some
part in the phase I hypotensive response. Here, we focussed on the
phase I hypotensive response to AEA and found it to be dependent on
SK1 but not SK2 activity. Indeed, previous studies have noted that
cannabinoids can modulate sphingolipid metabolism (Galve-Roperh
et al., 2000; Gustafsson et al., 2009; Mair et al., 2010). Moreover, SK1
has been shown to be involved in a number of agonist-induced re-
sponses involving S1P generation that subsequently acts via so called
‘inside-out’ signalling (Takabe et al., 2008).
It is possible that AEA employs a signalling pathway that induces
phosphorylation and activation of SK1 via extracellular signal-regulated
kinases-1/2, and we previously demonstrated this effect in isolated rat
coronary arteries in vitro (Mair et al., 2010). Our data do not rule out
activation of TRPV1 in response to injection of AEA. Indeed, generation
of S1P via SK1 may activate TRPV1 to produce bradycardia and also
activate S1P1 on vessels to produce vasodilation- both of which would
contribute to the phase I hypotension. In support of this, the brady-
cardic effect in response to 10mg/kg AEA tended to be lower in animals
treated with BML-258 (Supplementary Fig. 2) and a recent study has
claimed that S1P can sensitise TRPV1 channels on sensory neurons to
stimuli (Langeslag et al., 2014). Activation of CB2 receptors by AEA
may also be involved, based on our own data in the rat (Mair et al.,
2010) and an in vivo study where injection of the CB2 receptor agonist
HU-308 induced hypotension (Hanus et al., 1999). An indirect effect of
SK1 is also a possibility since sphingosine can act as a CB1 antagonist
and may blunt the AEA response in animals pretreated with an SK1
inhibitor, where sphingosine is likely to accumulate (Paugh et al.,
2006). In the mouse aorta, our in vitro data indicate that conversion of
sphingosine to S1P is required for vasodilatation to occur and that
sphingosine itself does not mediate a vasodilator effect. Blocking this
conversion in vivo using BML-258 or SKi would prevent the vasodilator
actions of endogenous S1P. Interestingly, the presence of the en-
dothelium prevented relaxation to S1P albeit that this was in a conduit
vessel. Further experiments are required to assess the vasodilator effects
Fig. 3. Effect of the S1P1 antagonist W146 on the peak hypotensive response to
i.v. administration of anandamide. (A) Mice were pre-treated with either ve-
hicle or W146 (10mg/kg) for 30min prior to baseline MAP measurements.
n= 6–12. (B and C) Baseline MAP and systolic BP values were compared to the
peak hypotensive response following increasing doses of anandamide.
*P < 0.05 and ***P < 0.001, n=5–6, two-way ANOVA.
F.H. Greig et al. European Journal of Pharmacology 842 (2019) 1–9
5
of S1P in an endothelium-intact resistance vessel which would be more
relevant to modulating total peripheral resistance.
4.3. Effect of S1P1 antagonist on the response to anandamide
The S1P1 antagonist W146, at a dose used in previous studies (Oo
et al., 2011; Tarrason et al., 2011), had a tendency to inhibit the hy-
potensive response to AEA. However, what was striking was the effect
of W146 pretreatment on the change in systolic BP in response to AEA
injection. The fall in systolic BP was inhibited by W146 but the fall in
diastolic BP in response to AEA was preserved. This will lead to a rise in
pulse pressure which is determined by a number of factors including the
stroke volume of the heart, compliance of the aorta and the resistance
to flow in the arterial tree. S1P1 is the predominant isoform expressed
on cardiac myocytes (Means and Brown, 2009) and activation causes a
negative inotropic effect via Gi and decreased cAMP within the cardi-
omyocytes. Consequently, blocking S1P1 may lead to an increase in the
force of contraction of the heart and an increased pulse pressure fol-
lowing AEA administration. What causes this effect remains to be de-
termined but it is unlikely to be via an action of AEA at CB receptors
since these are Gi linked and would therefore mediate negative in-
otropy and chronotropy. In the absence of W146, S1P generated by
injection of AEA may blunt the reflex rise in stroke volume, leading to a
fall in measured systolic BP. However, W146 may also affect vascular
compliance which would increase the pulse pressure and, as we have
demonstrated in vitro where preincubating aortic rings with W146
Fig. 4. Responses to sphingosine and S1P in the presence and absence of a SK inhibitor and S1P receptor antagonists in denuded mouse aortic rings. (A) Vessels were
pre-treated with the dual SK1/2 inhibitor SKi prior to U46619-induced contraction. n=3–9. (B) Dose-response to sphingosine and in the presence of SKi (10 μM)
were produced. *P < 0.05 versus sphingosine alone, n=3–9, two-way ANOVA. (C) Vessels were pre-treated with selective S1P1 antagonist W146 or the S1P1/3
antagonist, VPC 23019 (both 10 μM) prior to U46619-induced contraction. n=5–9. (D) Dose-response to S1P in the presence and absence of W146 and VPC 23019
were produced. (E) The BKCa channel opener NS1619 produced a vasodilation in endothelium-intact aortic rings which was not affected by either W146 or VPC
23019. ***P < 0.001 versus S1P alone, n= 5–9, two-way ANOVA.
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almost completely blocked the relaxation in response to S1P. Thus if
AEA is causing hypotension through generation of S1P, then inhibition
of S1P1 in the aorta (and perhaps also resistance arterioles) may ulti-
mately lead to decreased relaxation and an increase in pulse pressure.
4.4. Vascular actions of sphingosine and S1P
In this study, S1P and sphingosine both elicited a modest vasodi-
lator response in denuded mouse aortic rings. However, very little re-
laxation was observed in aortic rings with intact endothelium which is
in contrast to the results presented by others (Roviezzo et al., 2014). To
our knowledge, this is the first study to characterise the vascular actions
of sphingosine in mouse aorta. Our results agree with the effects in
porcine aorta (Hsiao et al., 2005) and coronary arteries (Murohara
et al., 1996) but are in contrast to studies reported in rat aortae and
mesenteric arteries where there was no effect, and in rat renal arteries
where there was a vasoconstriction (Johns et al., 1999; Bischoff et al.,
2000b). Sphingosine may inhibit Ca2+ flux from the sarcoplasmic re-
ticulum and L-type Ca2+ channels as observed in cardiomyocytes
(McDonough et al., 1994) or it may inhibit protein kinase C, which is
activated by U46619 and has contraction-promoting effects (Studer
et al., 1994). However, since we found that the dual SK1/2 inhibitor,
SKi prevented the relaxation to sphingosine, we conclude that meta-
bolism of sphingosine to S1P and a direct relaxation of VSMCs is the
likely mechanism in denuded mouse aortae. S1P is generally reported to
constrict denuded vessels (Bischoff et al., 2000b) and to dilate only
endothelium-intact mouse and rat thoracic aorta (Nofer et al., 2004;
Roviezzo et al., 2006). However, we found S1P to relax denuded aortic
rings and this was of a similar magnitude to what we observed in de-
nuded rat coronary artery (Mair et al., 2010).
VSMC abundantly express S1P2 and S1P3 (Means and Brown, 2009),
both of which have been linked to increases in intracellular Ca2+ and
vasoconstriction, making it unlikely that S1P induces relaxation
through these receptors. We speculated that S1P1 may be the receptor
responsible for S1P-mediated vasodilation. Preincubation of vessels
with W146 significantly inhibited the relaxation to S1P, suggesting that
S1P1 is indeed the main subtype responsible for S1P-induced vasodi-
lation in this vessel. Use of the combined S1P1/3 antagonist did not have
a significantly greater effect than W146, suggesting that S1P3 did not
contribute significantly to the response in the mouse aorta. Curiously,
in endothelium-intact vessels, the vasodilator response to S1P was not
seen, despite S1P1 being detected immunohistochemically on the en-
dothelium. It is possible that in a conduit vessel, such as the aorta, the
endothelial S1P1 receptors are less sensitive or that another S1P re-
ceptor subtype opposes the vasodilation mediated via activation of S1P1
in the VSMCs.
Other studies in resistance vessels rather than conduit vessels have
also reported expression of S1P1 receptors. In the rat, Yin et al. (2012),
demonstrated expression in cardiac microvasculature while a study by
Hemmings et al. (2004) used Western blotting of homogenised me-
sentery and showed expression of S1P1 receptor which was decreased in
aged rats. In human mesenteric and skeletal muscle resistance vessels,
expression of S1P1–3 receptors was detected (Hui et al., 2015). In that
study the authors noted wide variability in receptor expression between
vascular beds (and between species when they studied expression in
mouse cremaster skeletal muscle arteries) and so it seems probable that
a balance exists between dilator and constrictor effects of S1P depen-
dent on receptor distribution, abundance and access of S1P to these
receptors.
4.5. Conclusions
In conclusion, this study provides evidence that the SK1/S1P-axis is
important not only in physiological BP regulation but is necessary for
Fig. 5. S1P1 immunostaining in the en-
dothelium and medial vascular smooth muscle
cells of aortae from vehicle- and W146-treated
mice. Representative photomicrographs
(n=6) of sections stained with S1P1 and
counterstained with haematoxylin. Specific
staining is seen as a brown colour and was vi-
sualised via a peroxidase-DAB method (mag-
nification × 400 for all panels).
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the phase I hypotension in response to AEA. Generation of S1P in re-
sponse to AEA likely activates S1P1 to reduce TPR and lower MAP. In
conduit vessels, this is at the level of the VSMCs while in resistance
vessels, an effect of S1P receptors on the endothelium may also con-
tribute, although this remains to be determined. These findings have
important implications in our understanding of the hypotensive and
cardioprotective actions of cannabinoids and may aid the identification
of novel pharmacological targets for the treatment of hypertension.
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